Provided by Tiger Trade Technology Pte. Ltd.

Panbela Therapeutics, Inc.

0.0050
-0.0061-54.95%
Volume:100.00
Turnover:0.50
Market Cap:24.27K
PE:0.00
High:0.0050
Open:0.0050
Low:0.0050
Close:0.0111
52wk High:0.4729
52wk Low:0.0000
Shares:4.85M
Float Shares:4.85M
Volume Ratio:0.19
T/O Rate:0.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-34.5100
EPS(LYR):-316.5211
ROE:-798.16%
ROA:-229.77%
PB:-0.00
PE(LYR):0.00

Loading ...

Company Profile

Company Name:
Panbela Therapeutics, Inc.
Exchange:
EXPERT
Establishment Date:
2011
Employees:
8
Office Location:
712 Vista Boulevard,Suite 305,Waconia,Minnesota,United States
Zip Code:
55387
Fax:
- -
Introduction:
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.